The Patent Finder

Tisento Therapeutics Inc.

13 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for TREATMENT OF CNS DISEASES WITH sGC STIMULATORS (US 11,690,828) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due Feb 22, 2027
    The maintenance fee for sGC STIMULATORS (US 11,731,977) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for sGC STIMULATORS (US 10,472,363) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Aug 13, 2027
    The maintenance fee for sGC STIMULATORS (US 11,897,887) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,472,363sGC STIMULATORS
In force
 · High confidence
In forceHigh confidence
US 10,858,363SGC Stimulators
In force
 · High confidence
In forceHigh confidence
US 11,731,977sGC STIMULATORS
In force
 · High confidence
In forceHigh confidence
US 11,180,493SGC Stimulators
In force
 · High confidence
In forceHigh confidence
US 11,690,828TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
In force
 · High confidence
In forceHigh confidence
US 12,435,080sGC STIMULATORS
In force
 · High confidence
In forceHigh confidence
US 12,054,489Substituted Amidrazones as Intermediates in the Process for Preparing Soluble Guanylate Cyclase Stimulators
In force
 · High confidence
In forceHigh confidence
US 11,466,014Process for Preparing Soluble Guanylate Cyclase Stimulators
In force
 · High confidence
In forceHigh confidence
US 11,466,015CRYSTALLINE FORMS OF 8-(2-Fluorobenzyl)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-Triazol-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS
In force
 · High confidence
In forceHigh confidence
US 12,122,782Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 3 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited